in

Presently, over 240 ADC therapy candidates are being evaluated in clinical / preclinical stages for

With six marketed drugs, ADCs are presently recognized as a potent class of targeted anticancer therapies, with the potential to be used to treat a variety of other disease indications. The success of such products can be attributed to their ability to effectively identify and eliminate disease associated cells / pathogens, with substantially lower risk of treatment related side effects.

 

To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this link

 

The USD 15 billion (by 2030) financial opportunity within this market has been analyzed across the following segments:

Type of Payload

MMAE

DM4

Camptothecin

DM1

MMAF

Others

  • Type of Linker
  • VC
  • Sulfo-SPDB
  • SMCC
  • VA
  • Hydrazone
  • Others

Target Indication

  • Breast cancer
  • Lymphoma
  • Leukemia
  • Urothelial cancer
  • Lung cancer
  • Ovarian cancer
  • Others

 

Target Antigen

  • CD30
  • HER2
  • CD22
  • CD33
  • Others

Technology Providers

  • Seattle Genetics
  • ImmunoGen
  • StemCentRx
  • Immunomedics
  • Others

Key Geographical Regions

North America

Europe

Asia Pacific

 

The Antibody Drug Conjugates Market (5th Edition), 2019-2030 report features the following companies, which we identified to be key players in this domain: 

Bristol Myers Squibb

GlaxoSmithKline

Incyte

Novartis

Trillium Therapeutics

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction

Market Overview

5. Company and Drug Profiles

6. Key Therapeutic Areas

7. Key Opinion Leaders

8. Target Competitiveness Analysis

9. Partnerships and Collaborations

10. Funding and Investment Analysis

11. Patent Analysis

12. Academic Grants

13. Key Commercialization Strategies

14. Promotional Analysis

 

15. Combination Therapies

 

16. Novel Conjugation Technology Platforms

 

17. Assessment of Non-Clinical Data, First in Human Dosing

 

18. Cost Price Analysis

 

19. Case Study: Contract Manufacturing of ADC

 

20. Case Study: Companion Diagnostics for ADC Therapeutic

 

21. Market Forecast and Opportunity Analysis

 

22. Swot Analysis

23. Conclusion

24. Executive Insights

25. Appendix 1: Tabulated Data

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com  

This post was created with our nice and easy submission form. Create your post!

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings

Loading…

0

What do you think?

Ripple Reveals Push To Expand Institutional XRP Liquidity in Asia, Launches Hiring Spree for RippleX

Ripple Reveals Push To Expand Institutional XRP Liquidity in Asia, Launches Hiring Spree for RippleX

Pantera Capital Co-CIO Explains Why 'DeFi Is the Future of Finance'

Pantera Capital Co-CIO Explains Why ‘DeFi Is the Future of Finance’